153 related articles for article (PubMed ID: 36317514)
1. Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B.
Hui KY; Fung J; Cheung KS; Mak LY; Seto WK; Yuen MF
Gut Liver; 2023 Mar; 17(2):280-287. PubMed ID: 36317514
[TBL] [Abstract][Full Text] [Related]
2. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function.
Chien TL; Wang JH; Kee KM; Chen CH; Hung CH; Lu SN
PLoS One; 2016; 11(12):e0166543. PubMed ID: 27935953
[TBL] [Abstract][Full Text] [Related]
3. Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
Ungtrakul T; Sriprayoon T; Kusuman P; Chunnuan P; Soonklang K; Sornsamdang G; Auewarakul CU; Tanwandee T
Medicine (Baltimore); 2017 Mar; 96(13):e6554. PubMed ID: 28353619
[TBL] [Abstract][Full Text] [Related]
4. Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients.
Yeo YH; Tseng TC; Hosaka T; Cunningham C; Fung JYY; Ho HJ; Kwak MS; Trinh HN; Ungtrakul T; Yu ML; Kobayashi M; Le AK; Henry L; Li J; Zhang J; Sriprayoon T; Jeong D; Tanwandee T; Gane E; Cheung RC; Wu CY; Lok AS; Lee HS; Suzuki F; Yuen MF; Kao JH; Yang HI; Nguyen MH
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00196. PubMed ID: 33094953
[TBL] [Abstract][Full Text] [Related]
5. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
6. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B.
Leung RH; Hui RW; Mak LY; Mao X; Liu KS; Wong DK; Fung J; Seto WK; Yuen MF
J Hepatol; 2024 Mar; ():. PubMed ID: 38527527
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
9. Artificial neural network accurately predicts hepatitis B surface antigen seroclearance.
Zheng MH; Seto WK; Shi KQ; Wong DK; Fung J; Hung IF; Fong DY; Yuen JC; Tong T; Lai CL; Yuen MF
PLoS One; 2014; 9(6):e99422. PubMed ID: 24914537
[TBL] [Abstract][Full Text] [Related]
10. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.
Broquetas T; Garcia-Retortillo M; Hernandez JJ; Puigvehí M; Cañete N; Coll S; Cabrero B; Giménez MD; Solà R; Carrión JA
PLoS One; 2017; 12(11):e0188303. PubMed ID: 29190670
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
[TBL] [Abstract][Full Text] [Related]
12. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
[TBL] [Abstract][Full Text] [Related]
14. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
15. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
Coffin CS; Haylock-Jacobs S; Doucette K; Ramji A; Ko HH; Wong DK; Elkhashab M; Bailey R; Uhanova J; Minuk G; Tsoi K; Wong A; Ma MM; Tam E; Brahmania M; Nudo C; Zhu J; Lowe CF; Osiowy C; Lethebe BC; Congly SE; Chan EKH; Villasis-Keever A; Sbarigia U; Cooper CL; Fung S
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560672
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
18. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients.
Chan HL; Wong GL; Tse CH; Chan HY; Wong VW
J Infect Dis; 2011 Aug; 204(3):408-14. PubMed ID: 21742839
[TBL] [Abstract][Full Text] [Related]
19. Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study.
Nagaoka S; Abiru S; Komori A; Sasaki R; Bekki S; Hashimoto S; Saeki A; Yamasaki K; Migita K; Nakamura M; Ezaki H; Yatsuhashi H
Hepatol Res; 2016 Mar; 46(3):E89-99. PubMed ID: 25951079
[TBL] [Abstract][Full Text] [Related]
20. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
